<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
   <channel>
      <title>Drug Injury Lawyer Blog</title>
      <link>http://www.druginjurylawyerblog.com/</link>
      <description>Published by Pogust Braslow &amp; Millrood  </description>
      <language>en</language>
      <copyright>Copyright 2010</copyright>
      <lastBuildDate>Tue, 26 Jan 2010 14:06:48 -0500</lastBuildDate>
      <generator>http://www.sixapart.com/movabletype/?v=3.33</generator>
      <docs>http://blogs.law.harvard.edu/tech/rss</docs> 

            <item>
         <title>Graco Stroller Recall</title>
         <description><![CDATA[<p>On Wednesday, January 20, 2010, <a href="http://www.newellrubbermaid.com/public/index.aspx">Newell Rubbermaid</a> announced that it is recalling 1.5 million baby strollers after receiving 7 reports of amputations or lacerations to children’s' fingers.  The products' canopy hinges are to blame for the injuries, which occurred when children got their fingers stuck in the canopy as it was being opened or closed.  <br />
 <br />
</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2010/01/graco_stroller_recall_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2010/01/graco_stroller_recall_1.html</guid>
         <category></category>
         <pubDate>Tue, 26 Jan 2010 14:06:48 -0500</pubDate>
      </item>
            <item>
         <title>Meridia Causing Heart Problems?</title>
         <description><![CDATA[<p>Last week, the Food and Drug Administration (FDA) requested that drug manufacturer Abbott Laboratories strengthen the product labeling for its weight-loss drug Meridia (sibutramine) to disclose an increased risk of heart attack and stroke in patients with a history of cardiovascular disease.</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2010/01/meridia_causing_heart_problems_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2010/01/meridia_causing_heart_problems_1.html</guid>
         <category></category>
         <pubDate>Tue, 26 Jan 2010 13:06:41 -0500</pubDate>
      </item>
            <item>
         <title>Tylenol Recall by Johnson &amp; Johnson</title>
         <description><![CDATA[<p>Last week, drug manufacturer Johnson & Johnson announced an expansive recall of a variety of products, including Tylenol, Motrin, and Benadryl, after complaints of an “unusual moldy, musty or mildew-like” odor accompanying the products.</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2010/01/tylenol_recall_by_johnson_john.html</link>
         <guid>http://www.druginjurylawyerblog.com/2010/01/tylenol_recall_by_johnson_john.html</guid>
         <category></category>
         <pubDate>Tue, 19 Jan 2010 08:28:32 -0500</pubDate>
      </item>
            <item>
         <title> CT Scan Radiation Causing Cancer </title>
         <description><![CDATA[<p>In October, we alerted readers that the FDA became aware of numerous radiation overexposures during CT scans at a particular facility, with patients receiving radiation doses that were approximately eight times the expected level.  The article noted that this situation may reflect more widespread problems with CT quality assurance programs and may not be isolated to this particular facility - putting patients at increased risk for long-term radiation effects.</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/12/ct_scan_radiation_causing_canc_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/12/ct_scan_radiation_causing_canc_1.html</guid>
         <category>Medical Devices</category>
         <pubDate>Wed, 16 Dec 2009 15:32:26 -0500</pubDate>
      </item>
            <item>
         <title>New Safety Warnings About Diabetes Drug and Kidney Functions</title>
         <description><![CDATA[<p>Recently, <a href="http://www.cnn.com/2009/HEALTH/11/04/byetta.diabetes.risks/">the safety warnings were strengthened </a>for the diabetes drug Byetta relating to the risks of pancreatitis and the medicine’s use by patients with severe kidney disease. Specifically, the US Food and Drug Administration ("FDA") <a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm188656.htm">notified healthcare professionals</a> of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. </p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/11/new_safety_warnings_about_diab_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/11/new_safety_warnings_about_diab_1.html</guid>
         <category>Adverse Drug Update</category>
         <pubDate>Fri, 06 Nov 2009 14:23:34 -0500</pubDate>
      </item>
            <item>
         <title>Video and Audio Cables: Are Consumers Paying More than Necessary?</title>
         <description><![CDATA[<p>Consumers have paid upwards of $100 for cables whose performance is equal to a standard $10 six-foot HDMI cable.   Many electronic stores and manufacturers have made claims that these “premium” cables outperform standard cables.  However, many well respected third party reviewers, such as cnet.com contend that this isn’t necessarily the case.  “Do you really need to spend that much money on a single HDMI cable?  Absolutely not – those cables are a rip-off” says <a href="http://consumerist.com/366674/cnet-says-cheap-hdmi-cables-just-as-good-as-pricey-ones">CNET</a>.  “And despite what salesman and manufacturers might tell you, there’s no meaningful difference between the $10 cable and the $50 cable.”<br />
</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/10/video_and_audio_cables_are_con.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/10/video_and_audio_cables_are_con.html</guid>
         <category>Consumer Protection</category>
         <pubDate>Wed, 21 Oct 2009 14:08:49 -0500</pubDate>
      </item>
            <item>
         <title>Even More Dangers of Taking SSRIs When Pregnant Revealed</title>
         <description><![CDATA[<p>According to a recently released <a href="http://abcnews.go.com/Health/wireStory?id=8757454#">Danish study</a>, pregnant women taking an SSRI were twice as likely to have pre-term delivery as other women, and their babies were also more likely to be admitted to an intensive care unit after delivery.  Specifically, women taking an SSRI delivered their baby an average of five days earlier and babies exposed to antidepressants during pregnancy were far more likely to have a five-minute Apgar score -- a measure of a newborn's health scored between 0 and 10 -- of seven or below.  Any score below seven is generally regarded as low. </p>

<p>Additionally, <a href="http://www.webmd.com/baby/news/20090924/antidepressants-linked-to-birth-defect">the study found</a> that women who take more than one SSRI quadrupled the risk of their babies experiencing a septal heart defect, which is a defect in the wall that divides the heart’s left and right sides.  For those women taking only one SSRI, the study revealed that use of Celexa and Zoloft early in pregnancy doubled and tripled the risk for the heart defect, respectively.  While the association between SSRIs and birth defects has been reported for several years, this is the first study to specifically highlight the increased risk with Celexa and Zoloft.</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/10/even_more_dangers_of_taking_ss_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/10/even_more_dangers_of_taking_ss_1.html</guid>
         <category>Adverse Drug Update</category>
         <pubDate>Sun, 11 Oct 2009 20:55:20 -0500</pubDate>
      </item>
            <item>
         <title>Forced to Rent a Cable Box?</title>
         <description><![CDATA[<p>Have you looked at your cable bill and found that you are paying $5, $6, and even $10 a month to rent a cable box from your service provider? Ever wonder why you cannot simply purchase your cable box or rent a cheaper box from another company? Many consumers are limited in subscribing to certain cable companies; however, numerous cable companies take advantage of  consumers by charging $60 or more EACH year to rent a set-top box that should cost no more than a DVD player to buy.</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/10/forced_to_rent_a_cable_box.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/10/forced_to_rent_a_cable_box.html</guid>
         <category>Consumer Protection</category>
         <pubDate>Fri, 02 Oct 2009 09:46:09 -0500</pubDate>
      </item>
            <item>
         <title>Another Medtronic Recall For Infusion Pumps</title>
         <description><![CDATA[<p>In August 2009, <a href="http://www.medtronic.com/isomedsc/SC_IsoMed_HCP_Letter.pdf">Medtronic began informing physicians</a> for the first time that, contrary to the labeling, its Sutureless Connector (SC) intrathecal catheters were incompatible with IsoMed Infusion Pump Model 8472, a drug delivery system for which the catheters were not designed.   On September 14, 2009, <a href="http://wwwp.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1252933853054&lang=en_US">the US Food and Drug Administration ("FDA") notified Medtronic</a> that it considers the notification a Class I medical device recall, the strongest notice that the FDA can issue, because accidental use of the catheters with the wrong pump may lead to disruptions of therapy and revision surgery, which pose a risk of serious injury or death.  This incompatibility is a design defect and not a result of how the pump is implanted. In fact, it may appear to be connected and secured, but a physical interference between the catheter and the infusion pump may lead to fluids leaking into surrounding tissues and the proper dose of drugs not being delivered. </p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/09/another_medtronic_recall_for_i_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/09/another_medtronic_recall_for_i_1.html</guid>
         <category>Medical Devices</category>
         <pubDate>Mon, 21 Sep 2009 13:56:55 -0500</pubDate>
      </item>
            <item>
         <title>Unnecessary Replacement of Ink/Toner Cartridges Costing Consumers $$</title>
         <description><![CDATA[<p>Any printer or all-in one (print-copy-fax) machine purchased within the last few years comes with its own software to install on your computer.  This software includes updates regarding the amount of ink or toner remaining in the cartridge and provides reminders and warnings to replace your ink or toner cartridge as soon as a certain level is reached. However, recent tests have found that these indicators are requiring consumers to change or replace their cartridges before it is truly necessary, thereby wasting ink, toner, and consumers' money.  <br />
</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/08/unnecessary_replacement_of_ink_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/08/unnecessary_replacement_of_ink_1.html</guid>
         <category>Consumer Protection</category>
         <pubDate>Sat, 29 Aug 2009 15:21:49 -0500</pubDate>
      </item>
            <item>
         <title>Credit Solutions Unable to Explain Failures</title>
         <description><![CDATA[<p>As we <a href="http://www.druginjurylawyerblog.com/2009/05/ny_attorney_general_sues_two_debt_settlement_companie.html">reported here</a> in May, the NY Attorney General filed suit against two debt consolidation firms in New York alleging fraudulent and deceptive business practices.  Namely, the companies reportedly charge exorbitant consolidation fees while failing to ever eliminate any of the customer's debt.  The result for the customer is greater debt and a damaged credit score.  Following up on this growing trend last night, <a href="http://a.abcnews.com/Business/Story?id=7932088&page=3">ABC News </a>attempted to get answers to the questions that many consumers would like to know.  However, the VP of operations for Credit Solutation of America claimed to be ignorant on many issues. </p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/08/credit_solutions_unable_to_exp.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/08/credit_solutions_unable_to_exp.html</guid>
         <category>Consumer Protection</category>
         <pubDate>Mon, 24 Aug 2009 11:18:31 -0500</pubDate>
      </item>
            <item>
         <title>Risks of Heart Attack and Stroke with Asthma Drug Xolair</title>
         <description><![CDATA[<p>On July 16, 2009, the FDA <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm172399.htm">announced</a> that it has begun a safety review of <a href="http://www.gene.com/gene/products/information/immunological/xolair/">Genentech's</a> asthma drug <a href="http://www.webmd.com/drugs/drug-76302-xolair+subq.aspx">Xolair</a>  (omalizumab) after reports of an increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke. The Xolair safety review was prompted by interim results from an ongoing study of 5,000 patients with allergic asthma, in which half of the patients took Xolair and half did not.  The early results showed a "disproportionate increase" in certain cardiovascular and cerebrovascular problems in patients treated with Xolair. </p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/08/risks_of_heart_attack_and_stro_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/08/risks_of_heart_attack_and_stro_1.html</guid>
         <category>Adverse Drug Update</category>
         <pubDate>Sat, 15 Aug 2009 18:54:27 -0500</pubDate>
      </item>
            <item>
         <title>SSRIs and the Suicidality Risk: Class Numbers Belie a Deeper Story</title>
         <description><![CDATA[<p>On August 11, 2009, the British Medical Journal published an article detailing the results of a study aimed at measuring the association between modern antidepressants (Prozac, Paxil, Zoloft, Celexa, Lexapro, etc.) and increased suicidal thinking and conduct.  <a href="http://www.bmj.com/cgi/reprint/339/aug11_2/b2880">August 11, 2009 BMJ Article</a></p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/08/ssris_and_the_suicidality_risk_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/08/ssris_and_the_suicidality_risk_1.html</guid>
         <category>Adverse Drug Update</category>
         <pubDate>Fri, 14 Aug 2009 16:48:46 -0500</pubDate>
      </item>
            <item>
         <title>FDA Warns of Cancer Risks with TNF Blockers</title>
         <description><![CDATA[<p>On August 4, 2009, the <a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174449.htm">Food and Drug Administration</a> stated that it had completed its analysis of <a href="http://arthritis.about.com/od/brms/g/tnf.htm">tumor necrosis factor </a>(TNF) blockers and has concluded that there is an increased risk of lymphoma and other cancers associated with the use of these drugs in children and adolescents.  Therefore, the FDA said that a new cancer-related warning will be added to the black boxed warning that’s already on this category of drugs, which includes Remicade, Enbrel, Cimzia, Simponi, and Humira.  Additionally, the FDA is requiring that the warning also be modified to specifically reflect the occurrence of leukemia and new-onset psoriasis in patients of all ages being treated with TNF blockers.  The current boxed warning only alerts users to a risk of serious infections that can be fatal.  <br />
</p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/08/fda_warns_of_cancer_risks_with_1.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/08/fda_warns_of_cancer_risks_with_1.html</guid>
         <category>Adverse Drug Update</category>
         <pubDate>Mon, 10 Aug 2009 12:51:07 -0500</pubDate>
      </item>
            <item>
         <title>Recent Consumer Product Recalls</title>
         <description><![CDATA[<p>The following products have experienced problems resulting in their recall:</p>

<p>13-foot Square Trampolines. The straps supporting the top of the trampoline’s enclosure to the poles can fail. The enclosure could drop if these straps break, posing a fall risk. Skywalker Holdings LLC, (866) 603-5867 or <a href="http://www.skywalkertrampolines.com">www.skywalkertrampolines.com</a></p>

<p>2005 Novara Trionfo Bicycles. The fork can separate from the steerer tube, which can cause the rider to lose control. Recreational Equipment Inc. (REI), (800) 426-4840 or <a href="http://www.rei.com">www.rei.com</a></p>]]></description>
         <link>http://www.druginjurylawyerblog.com/2009/08/recent_consumer_product_recall.html</link>
         <guid>http://www.druginjurylawyerblog.com/2009/08/recent_consumer_product_recall.html</guid>
         <category>Product Liability</category>
         <pubDate>Sat, 08 Aug 2009 14:36:04 -0500</pubDate>
      </item>
      
   </channel>
</rss>
